Latest Breaking News On - சூசன் பிரான்சிஸ் - Page 1 : comparemela.com

Posted on 1113 Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70 th Annual Scientific Session (ACC.21), with simultaneous publication in The Lancet. At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales. Moreover, a greater proportion of mavacamten patients achieved a very large, clinically meaningful improvement (≥20 points) in the KCCQ OSS, compared to placebo, 36% [33/92] vs. 15% [13/88]. A change of at least 5 points is required to be considered clinically significant. These results were presented today

Johna spertusBristol myers squibbSusan francisAmerican college of cardiologyClinical researchi sessionExchange commissionUniversity of missouriAmerican collegeAnnual scientific sessionFeatured clinical researchi sessionHot topics channelClinical directorOutcomes researchSaint lukeMid america heart instituteLauer missouri endowed chair